Important Update for Agenus Inc. Investors
In a significant development, the Rosen Law Firm is bringing attention to all those who purchased securities of Agenus Inc. (NASDAQ: AGEN). The firm emphasizes the urgency for investors, as an important deadline is approaching soon. If you have invested in Agenus securities between specific dates set by the lawsuit, this information could be vital for your financial future.
Understanding the Class Period
The class period defined in the securities class action involves purchases made between January 23, 2023, and July 17, 2024. This time frame is crucial because it sets the parameters for which investors could be eligible to join the class action. There’s a critical deadline for plaintiffs, set for November 5, 2024, which investors must keep in mind.
Benefits of Joining the Class Action
By joining the class action against Agenus, investors can potentially receive compensation without incurring any out-of-pocket expenses. The arrangement typically involves a contingency fee, meaning that no legal fees are paid unless the case is won. This allows investors a chance to reclaim investment losses without financial risk upfront.
Next Steps for Investors
For anyone who has purchased Agenus securities within the class period, it’s important to take immediate action. You can find detailed information on how to join the class action by reaching out directly to the Rosen Law Firm. They provide avenues for secure registration through forms and direct contact with their attorneys.
Why Choose Rosen Law Firm
The Rosen Law Firm stands out due to its impressive track record in handling securities class actions. They notably represent investors globally, focusing on complex securities litigation that protects shareholders. Not only does the firm boast high-profile settlements, but recent rankings acknowledge their consistent performance, earning them respect within the legal community.
Details of the Allegations Against Agenus
The lawsuit against Agenus asserts that during the class period, the company issued misleading statements regarding the effectiveness of its combination therapies, particularly botensilimab and balstilimab. The allegation includes claims that the efficacy of these therapies for treating conditions like pancreatic cancer and cervical cancer was overstated, leading investors to make uninformed decisions.
Potential Damages for Investors
Since the lawsuits indicate that these statements led investors to suffer losses, the ramifications could be significant. As the true efficacy of the medications came to light, those who purchased shares during the misrepresented timeframes found themselves facing potential losses in their investments.
Stay Informed and Take Action
It’s crucial for all investors in Agenus Inc. to stay informed. The market can shift quickly, and decisions should be made based on accurate and timely information. The Rosen Law Firm invites you to consider your position and encourages taking proactive steps to potentially recover losses.
Frequently Asked Questions
What is the class period for the Agenus securities class action?
The class period runs from January 23, 2023, to July 17, 2024.
What is the lead plaintiff deadline?
The deadline to move the Court to serve as a lead plaintiff is November 5, 2024.
Can I join the class action without any costs?
Yes, joining the class action typically involves no out-of-pocket costs through a contingency fee arrangement.
What allegations are being made against Agenus?
The lawsuit claims that Agenus made misleading statements regarding the effectiveness of its therapies, which resulted in investor losses.
How can I contact the Rosen Law Firm for assistance?
You can reach out to Phillip Kim, Esq. at the Rosen Law Firm either by phone or via email for further information.
